alexa DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells.
Oncology

Oncology

Cancer Medicine & Anti Cancer Drugs

Author(s): Smurnyy Y, Cai M, Wu H, McWhinnie E, Tallarico JA,

Abstract Share this page

Abstract Identification and validation of drug-resistant mutations can provide important insights into the mechanism of action of a compound. Here we demonstrate the feasibility of such an approach in mammalian cells using next-generation sequencing of drug-resistant clones and CRISPR-Cas9-mediated gene editing on two drug-target pairs, 6-thioguanine-HPRT1 and triptolide-ERCC3. We showed that disrupting functional HPRT1 allele or introducing ERCC3 point mutations by gene editing can confer drug resistance in cells. This article was published in Nat Chem Biol and referenced in Cancer Medicine & Anti Cancer Drugs

Relevant Expert PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords